Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

National Institutes of Health

MODERATE Tx General

Strategy Notes

—

Key Materials

—

Your Notes

Status & Deadline

Status: INELIGIBLE
Deadline: 08/18/2027
Cycle: —
Amount: —
Type: grant
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-22 OPEN → INELIGIBLE · The Blueprint Neurotherapeutics Network (BPN) Biologic-based Drug Discovery and Development program requires the applicant to be a U.S.-based entity (e.g., small business, academic institution, or nonprofit) with a U.S. principal investigator. Eniola Ayodele Olutogun is an independent researcher based in Lagos, Nigeria, with no U.S. institutional affiliation, and the program does not support foreign applicants without a U.S. partner institution.